DLC1: a significant GAP in the cancer genome
DLC1: a significant GAP in the cancer genome
复制标题
DOI：
10.1101/gad.1691408
复制
发表时间：
2008-07-01
影响因子：
10.5
通讯作者：
Hall, Alan
中科院分区：
文献类型：
--
作者：
Lahoz, Aurelia;Hall, Alan
Rho GTP酶被认为对人类癌症的发生和发展做出了重要贡献，但缺乏类似于影响RAS的体细胞突变形式的直接证据。薛及其同事最近在《基因与发展》杂志上的一项研究(1439-1444页)现在提供了体内证据，表明Rho的负调控基因DLC1是一种肿瘤抑制基因，在乳腺癌、结肠癌和肺癌等常见癌症中缺失的频率几乎与P53一样高。
Rho GTPases are believed to make important contributions to the development and progression of human cancer, but direct evidence in the form of somatic mutations analogous to those affecting Ras has been lacking. A recent study in Genes & Development by Xue and colleagues (pp. 1439-1444) now provides in vivo evidence that DLC1, a negative regulator of Rho, is a tumor suppressor gene deleted almost as frequently as p53 in common cancers such as breast, colon, and lung.